No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TEVA Teva Pharmaceutical Industries
- 17.280
- +0.180+1.05%
Close Jul 12 16:00 ET
- 17.030
- -0.250-1.45%
Post 19:43 ET
19.57BMarket Cap-41142P/E (TTM)
17.395High17.065Low7.44MVolume17.130Open17.100Pre Close128.27MTurnover0.66%Turnover RatioLossP/E (Static)1.13BShares17.69052wk High2.69P/B19.45BFloat Cap7.95052wk Low--Dividend TTM1.13BShs Float68.007Historical High--Div YieldTTM1.93%Amplitude3.107Historical Low17.240Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20
Piper Sandler analyst David Amsellem maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $24
UBS analyst Ashwani Verma maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $24.According to TipRanks data, the analyst has a success rate of 47.
Express News | Teva Pharmaceuticals : UBS Raises Target Price to $24 From $22
Express News | UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $24
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 41.26% UBS $22 → $24 Maintains Buy 06/27/2024 35.37% Jefferies $19 → $23 Maintains Buy 06/05/20
Argus Upgrades Teva to Buy, Cites Recent Drug Approvals
Comments
$Teva Pharmaceutical Industries(TEVA.US$ better than anticipated revenue growth 📈
MAYDAY!!!
🤣 hahaha, my favorite gif 🤣
🎵 Here's where the story ends
It's that little souvenir of a terrible year
Which makes my eyes feel sore
It's that little souvenir of a terrible year
Surprise, surprise, surprise 🎵
I'm going to try and get a post out. I'm really uncomfortable and sore, but there are some big moves and big news ahead.
A little Sundays to start the day
As I said, I'm fresh out of the hospital again. I've been oversleeping and much too tired 😫. I feel gu...
🤣 hahaha, my favorite gif 🤣
🎵 Here's where the story ends
It's that little souvenir of a terrible year
Which makes my eyes feel sore
It's that little souvenir of a terrible year
Surprise, surprise, surprise 🎵
I'm going to try and get a post out. I'm really uncomfortable and sore, but there are some big moves and big news ahead.
A little Sundays to start the day
As I said, I'm fresh out of the hospital again. I've been oversleeping and much too tired 😫. I feel gu...
loading...
21
4
its not bad if you hold it. it's just not my thing. too many swaps and derivatives for my liking.
$Teva Pharmaceutical Industries(TEVA.US$ & alvotechpr
📣 FDA approves SELARSDI (Ustekinumab-Aekn), biosimilar to Stelara® 🎉
▻ approved for both adult and pedia indications (plaque psoriasis & psoriatic arthritis)
▻ developed and manuf. using same type of cells and process used for Stelara 👨🔬
▻ to be marketed in US on or after 02/21/25 🗓️
📣 FDA approves SELARSDI (Ustekinumab-Aekn), biosimilar to Stelara® 🎉
▻ approved for both adult and pedia indications (plaque psoriasis & psoriatic arthritis)
▻ developed and manuf. using same type of cells and process used for Stelara 👨🔬
▻ to be marketed in US on or after 02/21/25 🗓️
3
1
$Teva Pharmaceutical Industries(TEVA.US$ Pray Kwan Yin bless teva
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
